Zenosense, Inc. (ZENO) Aims to Save Lives with Rapid Detection Medical Devices
Zenosense holds an exclusive global license agreement to develop and market medical devices primarily for hospitals and primary healthcare facilities. By identifying specific markers found in individual’s exhaled breath, Zenosense’s devices strive for the early detection of deadly bacteria as well as some cancers.
The company is currently developing two devices – one intended to detect “Super-Bug,” or Methicillin-resistant Staphylococcus aureus (MRSA), and the other to detect lung cancer. The devices utilize a common Electronic Nose technology platform that analyzes Volatile Organic Compounds (VOCs) present in the exhaled breath of patients.
MRSA infections account for approximately 23,000 deaths per year in the United States and are diagnosed with testing procedures that can take up to three days to complete. Zenosense, in collaboration with partner Zenon Biosystem, is developing a lower cost system that dramatically quickens discovery times.
The electronic process of detecting the disease is based on natural processes. For instance, trained dogs are able to detect prostate cancer in urine with near complete accuracy. This is done by leveraging the innate sophistication of the approximately 200 million olfactory cells in canine noses. This natural, learned detection is similar to Zenosense’s technology in that it uses an infinite number of sensors and software that in effect ‘learns’ to recognize VOCs of concern.
Experts in nanotechnology, sensors, high-level mathematics, molecular biology and biochemistry are central to the development of the company’s technology, as are established partnerships with hospitals and universities in the areas of microbiology, infectious disease and chromatography, among others.
As the company continues to advance the development of its technologies, Zenosense strives toward its ultimate goal is to sell its medical detection devices to care facilities in the healthcare sector and revolutionize the detection of deadly bacteria and cancer.
For more information visit www.zenosense.net
Please see disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.com
Zenosense holds an exclusive global license agreement to develop and market medical devices primarily for hospitals and primary healthcare facilities. By identifying specific markers found in individual’s exhaled breath, Zenosense’s devices strive for the early detection of deadly bacteria as well as some cancers.
The company is currently developing two devices – one intended to detect “Super-Bug,” or Methicillin-resistant Staphylococcus aureus (MRSA), and the other to detect lung cancer. The devices utilize a common Electronic Nose technology platform that analyzes Volatile Organic Compounds (VOCs) present in the exhaled breath of patients.
MRSA infections account for approximately 23,000 deaths per year in the United States and are diagnosed with testing procedures that can take up to three days to complete. Zenosense, in collaboration with partner Zenon Biosystem, is developing a lower cost system that dramatically quickens discovery times.
The electronic process of detecting the disease is based on natural processes. For instance, trained dogs are able to detect prostate cancer in urine with near complete accuracy. This is done by leveraging the innate sophistication of the approximately 200 million olfactory cells in canine noses. This natural, learned detection is similar to Zenosense’s technology in that it uses an infinite number of sensors and software that in effect ‘learns’ to recognize VOCs of concern.
Experts in nanotechnology, sensors, high-level mathematics, molecular biology and biochemistry are central to the development of the company’s technology, as are established partnerships with hospitals and universities in the areas of microbiology, infectious disease and chromatography, among others.
As the company continues to advance the development of its technologies, Zenosense strives toward its ultimate goal is to sell its medical detection devices to care facilities in the healthcare sector and revolutionize the detection of deadly bacteria and cancer.
For more information visit www.zenosense.net
Please see disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.com
